临床荟萃

• 论著 • 上一篇    下一篇

初诊时非霍奇金淋巴瘤患者外周血淋巴细胞与单核细胞比值在预后评估中的作用

  

  1. 1.北京市顺义区医院 血液内科,北京 100130;2.河北医科大学第三医院 血液内科,河北 石家庄  050051
  • 出版日期:2016-07-05 发布日期:2016-07-08
  • 通讯作者: 通信作者:孙丽霞,Email: sun2010@bjmu.edu.cn

Role of peripheral blood lymphocyte to monocyte ratio during preliminary diagnosis in prognosis assessment  of patients with nonHodgkin lymphoma

  1. 1.Department  of  Hematology,the Hospital of Shunyi District,Beijing, Beijing 100130,China;
    2.Department  of  Hematology,the Third Hospital of Hebei Medical University,Shijiazhuang 050051,China
  • Online:2016-07-05 Published:2016-07-08
  • Contact: Corresponding author: Sun Lixia,Email: sun2010@bjmu.edu.cn

摘要: 目的探讨初诊时外周血淋巴细胞与单核细胞比值(lymphocyte to monocyte ratio, LMR)在非霍奇金淋巴瘤(nonHodgkin lymphoma,NHL)患者预后评估中的作用。方法选取NHL患者56例,以LMR中位值2.17为阈值将56例患者分为两组,多因素分析观察年龄、性别、国际预后指数(IPI)以及外周血细胞绝对计数等与NHL预后的关系。结果56例NHL患者中位随访17个月(2~92个月),2年无疾病进展生存(PFS)和总体生存(OS)分别为(55.7±7.7)%和(76.1±6.4)%。多因素分析显示影响PFS的因素为LMR(HR=0.167, 95%CI=0.056~0.503,P=0.001); 影响OS的因素包括LMR(HR=0.120, 95%CI=0.014~0.998,P=0.050)和IPI(HR=4.763, 95%CI=0.982~23.114,P=0.053)。结论初诊时LMR是预测NHL患者预后的简单、易行的生物学标记。

关键词: 淋巴瘤, 非霍奇金;淋巴细胞与单核细胞比值;预后

Abstract: Objective To  investigate the effects of lymphocyte to monocyte ratio (LMR) on prognosis assessment of patients with nonHodgkin lymphoma (NHL). Methods Fiftysix patients were enrolled and classified into two groups according to the median value (2.17) of LMR. Multivariate analysis was used to evaluate the association of age, gender, international prognostic index (IPI), and absolute value of cell subsets in peripheral blood with progress free survival (PFS) and overall survival (OS). Results The two year probabilities of PFS and OS were (55.7±7.7)%  and  (76.1±6.4)%, respectively. Multivariate analysis showed that LMR was associated with PFS (HR=0.167,95%CI=0.0560.503,P=0.001). Factors associated with OS included LMR (HR=0.120,95%CI=0.0140.998,P=0.050) and IPI (HR=4.763, 95%CI=0.98223.114,P=0.053). Conclusion Our results suggested that LMR is a simple  and feasible biomarker during preliminary diagnosis that could be used to predict clinical outcomes of patients with nonHodgkin lymphoma.